AVANIR PHARMACEUTICALS (AVNR)

[Dakota Option]

Zacks Einsteins gave reason for downgrade, per: some analysts feel the next qter will result in a 0.14 loss--DUH, anyone following AVNR knows profits should come later on in 2011, besides that the potential of Nuedexta should result in an increase of pps, {and look for a possible takeover} you know when i see this horse--bleep it gets me sick because it shows no D-D on their part at all except a few analysts predictions for next qter-- bottom line --how can you short this when explosive news around the corner. bring it on